Goldman Sachs moved Oric Pharmaceuticals to a Buy rating and $15 price target from its Early Stage Biotech designation. The company's clinical data which demonstrated a "potentially differentiated profile" for inzimetostat in prostate cancer, the analyst tells investors in a research note. Goldman sees potential peak sales of $2.6B. If the Phase 1b profile is sustained, inzimetostat could capture meaningful share of a $7B addressable market of post-abiraterone metastatic castration-resistant prostate cancer, contends Goldman.
